ArriVent BioPharma, Inc. Common Stock earnings per share and revenue
On Nov 10, 2025, AVBP reported earnings of -0.83 USD per share (EPS) for Q3 25, missing the estimate of -0.80 USD, resulting in a -3.09% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.08% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of -0.86 USD, with revenue projected to reach -- USD, implying an increase of 3.61% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were ArriVent BioPharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, ArriVent BioPharma, Inc. Common Stock reported EPS of -$0.83, missing estimates by -3.09%, and revenue of $0.00, 0% as expectations.
How did the market react to ArriVent BioPharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.08%, changed from $18.05 before the earnings release to $18.60 the day after.
When is ArriVent BioPharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 01, 2026.
What are the forecasts for ArriVent BioPharma, Inc. Common Stock's next earnings report?
Based on 15
analysts, ArriVent BioPharma, Inc. Common Stock is expected to report EPS of -$0.86 and revenue of -- for Q4 2025.